Importantly, that effect was observed only among HER2 + participants (Hazard Ratio [HR] = 0.54; 95% CI: 0.30–0.98; P = 0.04) and not among participants with luminal breast cancer or the overall group of participants with mixed phenotypes. This evidence concerns the gene ERBB2 and breast carcinoma.